(Total Views: 314)
Posted On: 09/20/2019 8:37:53 AM
Post# of 154901
Re: xxxSchlingelxxx #8417
Here are the results of combo trial at 350mg dose.
The primary endpoint for combo trial was <50 c/ml at one week. It achieved 64%, far superior to maraviroc.
The main secondary outcome was <50 c/ml at 25 weeks. It achieved 81% for all patients.
Even at the 350 mg dose we would have been approvable.
You sold some shares. Today I'm buying more shares.
The primary endpoint for combo trial was <50 c/ml at one week. It achieved 64%, far superior to maraviroc.
The main secondary outcome was <50 c/ml at 25 weeks. It achieved 81% for all patients.
Even at the 350 mg dose we would have been approvable.
You sold some shares. Today I'm buying more shares.
(2)
(0)
